SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders debating whether guidance, subscriber engagement and ad growth can offset concerns about slowing growth and the content slate. Sentiment leans bearish amid the stocks decline and traders claims of repeated post-earnings selloffs, though some see low expectations as room for a rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound and heavy buying have fueled attention as traders anticipate the 80th-event trigger and final-analysis results for SELLASs Phase 3 REGAL trial of GPS. Some also read the CEOs anniversary remarks and planned ASH presence as possible buyout signals, but others stress there is no confirmed deal or trial result and that the price move may be trading activity.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly earnings and forward guidance are the dominant focus, particularly whether AI and data-center revenue can justify heavy capital spending. Traders are split between expecting a profitable report and rally and worrying about debt, spending, valuation, and an upcoming share unlock.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets reported Willow quantum-computing advanceusing magic state cultivation to cut errors roughly 40-foldhas sparked interest, though traders question whether it will matter to the stock near term as the share price remains weak. Conversation also centers on the upcoming earnings report and whether the recent pullback is a buying opportunity or reflects broader tech and AI-spending concerns.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs rise is being linked by traders both to strength across biotech and to the reported Silence Therapeutics acquisition, which some see as a sign of pharma interest in siRNA therapies relevant to Sareptas pipeline. Others view the move as a sector-driven bounce or short covering, and say upcoming DM1 and FSHD datanot a confirmed Sarepta-specific announcementwill be key.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas potential Monee fintech listing and launch of its Sea Cloud AI venture are fueling debate as shares sell off: some traders see a possible Monee separation and cloud investment as sources of uncertainty, while others argue the moves could unlock value and expand growth. The decline has intensified bearish technical commentary and speculation about insider selling, alongside bullish claims that the reaction is an overreaction.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are the main focus, with traders watching Google Cloud and Gemini for signs of growth. The discussion is divided between optimism about AI and cloud momentum and concern that heavy AI spending, alongside recent share-price weakness, could weigh on returns.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the detailed Phase 3 results for its personalized melanoma cancer vaccine with Merck at ESMO, following a positive topline readout. Bulls see the data as validation of its oncology platform, while skeptics warn that the sharp rally may have priced in strong results and could reverse on a sell-the-news reaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are falling despite a third-quarter earnings and revenue beat and a new buyback authorization, as investors focus on a narrowed full-year profit outlook with its midpoint unchanged rather than an upgrade. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and capital returns, and seeing the outlook and softer vehicle sales as reasons for caution.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is drawing attention amid broader funding and return concerns for AI-focused neoclouds, with traders also questioning the companys execution, dilution and delayed Horizon capacity. Co-CEO Daniel Roberts comments that data-center construction has been cash-funded and customer prepayments help finance GPUs are cited by bulls, but have not eased the bearish debate or frustration that IREN is lagging peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT) for violations of the securities laws. INVESTIGATION DETAILS: The...

PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival 

Equity

Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI). 


PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million$325 million from its previously issued $320 million$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If...

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PR Newswire NEW YORK, July 31, 2026 Phathom...

PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?

Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.


Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) PR Newswire...

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%  - Should You Buy?

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 7.5% - Should You Buy...

Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by...

Phathom Pharmaceuticals Q1 Earnings Call Highlights

Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized...

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Leerink opened coverage of PHAT with a Market Perform rating and a $10 price target.&nbsp;</li><li>Speaking the same day at Cantor Fitzgerald’s healthcare conference, Chief Executive Steve Basta and Chief Financial Officer Sanjeev Narula argued the commercial story for VOQUEZNA is stronger than the stock implies.</li><li>Basta also argued a second launch in the drug category could expand it rather than simply steal share.</li></ul><p>Shares of Phathom Pharmaceuticals (PHAT) slid about 7% on Wednesday after Leerink Partners opened coverage with a Market Perform rating and a $10 price target, arguing the company’s acid-reflux drug faces a crowded, price-sensitive market.</p><h2 class="st-heading-2">Cautious First Look From Leerink</h2><p>The firm said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI). The forecasts sit close to Street consensus, and the firm sees few near-term sources of upside to those estimates.</p><p>The $10 target sits only modestly above Tuesday’s closing price of $9.43. According to data from Koyfin, 10 of the 11 analysts covering PHAT stock rate it ‘Buy’ or higher while one rates it ‘Hold.’ The stock has an average 12-month price target of $21.50.</p><h2 class="st-heading-2">Management: Demand Is Not The Problem</h2><p>Speaking the same day at Cantor Fitzgerald’s healthcare conference, Chief Executive Steve Basta and Chief Financial Officer Sanjeev Narula argued the commercial story is stronger than the stock implies. Basta said about 30% to 40% of reflux patients still have significant pain on PPIs and that VOQUEZNA raises stomach pH more effectively. Among gastroenterologists surveyed, 97% believe the drug is more effective than older options, he said.</p><p>The bottleneck, he added, is “access friction”: prescribing it takes more work than writing a PPI, he said. “They (physicians) aren't confident always about whether or not their patient is actually going to be able to get the drug or what their patient's going to have to pay for the drug, and so that causes a bit of hesitation around when you prescribe,” Basta said.</p><h2 class="st-heading-2">Competition Concerns</h2><p>CEO Steve Basta also addressed the rival potassium-competitive acid blocker that the FDA is slated to decide on in the first quarter of 2027 and could potentially launch next year. “We have already got an established 3-year commercial lead in this space,” he said.</p><p>He pointed to healing data in erosive esophagitis, the more severe form of GERD. “In our phase III erosive esophagitis trial, 93% of erosive esophagitis patients healed within 8 weeks. In the competitive PCAB trial, it was around 85%.” That, he said, is “a really good indicator of how strong our drug is.”</p><p>Basta also argued a second launch could enlarge the category rather than simply steal share. A second product, he said, changes physician thinking from “this is a product that I need to think about relative to other products” to “this is now the new class of drugs.” In that shift, “the lead product in the category captures the majority of the uplift,” the CEO said. Phathom, he added, “should remain the leading product for a durable future in this space.”</p><h2 class="st-heading-2">VOQUEZNA Contribution</h2><p>VOQUEZNA is Phathom’s only commercial product and the company’s entire revenue engine. It is approved for erosive gastroesophageal reflux disease (GERD), heartburn from non-erosive GERD, and, in combination packs, H. pylori infection. In the second quarter, net sales reached a record $74.3 million, up 88% from a year earlier and 27% from the first quarter. The company filled about 325,000 prescriptions in the quarter, bringing the cumulative total since launch to roughly 1.7 million.</p><p>That growth has not been friction-free. On July 30, the company cut 2026 revenue guidance to $310 million–$325 million from $320 million–$345 million, citing prior-authorization delays, especially in milder GERD.</p><p>Cost cuts still helped Phathom post operating profitability excluding stock-based compensation in the second quarter. Cash stood at $182.5 million at midyear. Management still expects that adjusted profitability to hold for the rest of 2026 and cash-flow positivity in 2027.</p><h2 class="st-heading-2">Pipeline Catalysts Later This Year</h2><p>Phathom is currently attempting to expand the market for VOQUEZNA.</p><p>Enrollment is complete in a 95-patient mid-stage trial of VOQUEZNA in eosinophilic esophagitis; 12-week data are due in the fourth quarter. Positive results could open FDA talks on a later program, including pediatric work that might add six months of exclusivity.</p><p>Phathom also plans to start a late-stage study of as-needed dosing in non-erosive GERD in the same quarter.</p><h2 class="st-heading-2">How Did PHAT Retail Traders React?</h2><p>On Stocktwits, retail sentiment around PHAT stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/PHAT">PHAT stock</a> has fallen 47% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cme-group-names-jack-tobin-as-next-cfo-ahead-of-march-2027-leadership-transition/cZt7aL4RJzr">CME Group Names Jack Tobin As Next CFO Ahead Of March 2027 Leadership Transition</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Phathom Pharmaceuticals' logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI). 

PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.31
Prev Close	$7.01
Open	$7.06
Dividend Yield	0.00%
50-Day Moving Average	$8.13
Beta	1.07
Avg. Volume	1.27M
PE Ratio	-5.50

52-Week High	$18.31
52-Week Low	$6.52
Market Capitalization	$567.12M
EPS (Annual)	-$3.03
Price to Book	-1.63
Revenue Per Employee	$471,994.61

Feed

News

Sentiment

Earnings

Fundamentals

Info

PHAT Fundamentals